Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AQST
AQUESTIVE THERAPEUTICS, INC.
NASDAQ
$5.02
▼ DOWN 2.71% (-0.14)

KEY STATISTICS

Market Cap$629.84 M
52w High$7.55
52w Low$2.93
Dividend Yield—
Frequency—
P/E-7.72
Volume2.51M
Shares Out.125.47M

COMPANY

LEADERSHIP

Daniel Barber
CHIEF EXECUTIVE
Daniel Barber

COMPENSATION 2026

Salary$659,885
Stock Awards$1,547,342
Incentive Plan Pay$409,132
All Other Comp.$0
Total$3,493,559

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 25, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
147

PRICE TARGET

Target High$12.00
Target Low$6.00
Target Median$10.00
Target Consensus$9.75

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$11.02M
NOV
4
WED

PRICE

$5.02 ▼ DOWN 2.71% (−$0.14)
$5.02$5.10$5.179:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.02

About Aquestive Therapeutics, Inc.

https://www.aquestive.com ↗

Aquestive Therapeutics develops and markets innovative oral film products for neurological, psychiatric, and other medical conditions, with a pipeline of proprietary formulations targeting unmet needs globally.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT AQUESTIVE THERAPEUTICS, INC. IS KNOWN FOR

Anaphylm™ (epinephrine) Sublingual Film
Anaphylm™ (epinephrine) Sublingual Film

Anaphylm™ is a late-stage, sublingual epinephrine film for emergency allergic reactions, offering a less invasive alternative to injections, with FDA approval efforts ongoing despite prior regulatory challenges.

COMPETITORS

COMPETITOR
AMRX COMPARE
SPRY COMPARE
TEVA COMPARE
VTRS COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Manufacture and Supply Revenue$11.47M $11.98M ▲$8.79M ▼$11.91M ▲
License and Royalty Revenue$1.04M $852K ▼$5.39M ▲$1.33M ▼
CoDevelopment and Research Fees$302K $181K ▼$258K ▲$582K ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$10.12M $9.39M ▼$13.24M ▲$10.99M ▼
NonUS$2.68M $3.63M ▲$1.2M ▼$2.83M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
69
LISTED HERE
10
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.4M
IWM
0.02% · 2.8M
XPH
0.88% · 1.0M
SURI
1.61% · 278.7K
FSCC
0.26% · 197.8K
XRSG.L
0.02% · 98.8K
RSSL
0.02% · 51.3K
PILL
0.59% · 28.3K
QQQS
0.62% · 27.8K
BIB
0.02% · 4.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
45.51%
HOLDERS
262
TOP 12 OF 262 · RANKED BY POSITION SIZE
Bratton Capital Management, L.P.
9.8M sh · $40.72M
Blackrock, Inc.
8.1M sh · $33.57M
Rtw Investments, LP
7.4M sh · $30.89M
Vanguard Group Inc
5.9M sh · $38.06M
Blackrock Inc.
5.5M sh · $14.18M
Perceptive Advisors LLC
3.8M sh · $21.02M
Federated Hermes, Inc.
3.1M sh · $12.95M
State Street Corp
2.9M sh · $12.18M
Balyasny Asset Management L.P.
2.9M sh · $12.04M
Ecor1 Capital, LLC
2.6M sh · $16.96M
Geode Capital Management, LLC
2.6M sh · $10.91M
Samsara Biocapital, LLC
2.5M sh · $16.15M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Barber Daniel
Sale · 25.0K shares
2026-08-17
★
OFFICER: CHIEF COMMERCIAL OFFICER
Korczynski Sherry
Sale · 2.7K shares
2026-08-14
★
OFFICER: PRESIDENT AND CEO
Barber Daniel
Sale · 4.6K shares
2026-07-15
★
OFFICER: PRESIDENT AND CEO
Barber Daniel
Sale · 20.4K shares
2026-07-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OVERWEIGHT 1
MARKET OUTPERFORM 1
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Piper Sandler OVERWEIGHT JMP Securities MARKET OUTPERFORM Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
ERAS$18.03COMPARE
MLTX$14.99COMPARE
ARVN$9.18COMPARE
OFIX$9.70COMPARE
SNDL$1.35COMPARE
EBS$5.91COMPARE
AVXL$2.99COMPARE
SIGA$3.06COMPARE